TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6614411

Group type: EXPERIMENTAL
Intervention: Combination of retrobulbar local analgesia and light general anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 0
Study: 30678709

Group type: EXPERIMENTAL
Intervention: Web-based application (app) for lifestyle support in addition to traditional cardiac rehabilitation (CR) programs.
Number of subjects: 150
Study: 28984033

Group type: EXPERIMENTAL
Intervention: Diet intervention (D-group) received a 12-week diet intervention by a dietitian followed by monthly e-mails up to the 1-year follow-up.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (C-group) received a brochure on healthy eating with no further contact.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: D-group (after excluding women with new pregnancy)
Number of subjects: 110

Group type: COMPARATOR
Intervention: C-group (after excluding women with new pregnancy)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: D-group
Number of subjects: 110

Group type: COMPARATOR
Intervention: C-group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Women who gained weight from 1 to 2 years
Number of subjects: 110
Study: 26900698

Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament deficient group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 46
Study: 24598154

Group type: EXPERIMENTAL
Intervention: Methionine supplementation (0.5 mmol ⋅ kg(‐1) ⋅ d(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alanine (control)
Number of subjects: 12
Study: 22079052

Group type: EXPERIMENTAL
Intervention: Intraoral myofascial therapy (IMT) consisting of 2 treatment interventions per week for 5 weeks
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intraoral myofascial therapy plus education and self-care exercises (IMTESC)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 93
Study: 20941916

Group type: EXPERIMENTAL
Intervention: Cryostimulation and kinesytherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (MS patients without fatigue syndrome)
Number of subjects: 60
Study: 18701270

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 500 mg for 20-29 kg, 750 mg for 30-39 kg, 1000 mg for 40-49 kg, 1250 mg for >50 kg once a week for 8 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) once a week for 8 weeks
Number of subjects: 38
Study: 17023774

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (CRT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transanal excision (TAE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (Radical proctectomy)
Number of subjects: 32
Study: 12642834

Group type: COMPARATOR
Intervention: extensively hydrolyzed casein formula (eHF-C)
Number of subjects: 2252

Group type: COMPARATOR
Intervention: partially hydrolyzed whey formula
Number of subjects: 2252
Study: 10657327

Group type: EXPERIMENTAL
Intervention: External hip protectors
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (refusers)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Test-retest reliability study
Number of subjects: 194
Study: 9117023

Group type: EXPERIMENTAL
Intervention: Standard nasal cannula
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Reservoir nasal cannula
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Demand flow device
Number of subjects: 15

Group type: COMPARATOR
Intervention: All three systems
Number of subjects: 15
Study: 8139136

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study: 3524181

Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 31586969

Group type: EXPERIMENTAL
Intervention: First-time ASD
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Recurrent ASD
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both groups (First-time and Recurrent ASD)
Number of subjects: 56
Study: 28589472

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + saline solution (SSL) for 7 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + 2% chlorhexidine (CHX) gel for 7 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2% CHX gel for 7 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + saline solution (SSL) for 14 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + 2% chlorhexidine (CHX) gel for 14 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2% CHX gel for 14 days
Number of subjects: 72
Study: 27756349

Group type: EXPERIMENTAL
Intervention: Antenatal Guided Self Help, in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 24722260

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg over 10 minutes followed by a continuous infusion of 0.5 μg/kg/h throughout surgery)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 66
Study: 22229535

Group type: EXPERIMENTAL
Intervention: Male students
Number of subjects: 1833

Group type: EXPERIMENTAL
Intervention: Students who began drinking earlier in life
Number of subjects: 1833

Group type: COMPARATOR
Intervention: Living in on-campus housing
Number of subjects: 1833
Study: 20076850

Group type: EXPERIMENTAL
Intervention: Immediate-release AZD0837 150mg bid
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Immediate-release AZD0837 350mg bid
Number of subjects: 250

Group type: COMPARATOR
Intervention: Dose-adjusted warfarin
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both AZD0837 groups
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 250
Study: 18782078

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy (RTCT) with 5-FU-based treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative short-course RT alone (5 x 5 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative RTCT
Number of subjects: 0
Study: 15821396

Group type: EXPERIMENTAL
Intervention: Early exclusive breastfeeding (EBF)
Number of subjects: 4495

Group type: EXPERIMENTAL
Intervention: Early mixed breastfeeding
Number of subjects: 4495

Group type: EXPERIMENTAL
Intervention: Predominant breastfeeding
Number of subjects: 4495
Study: 12424553

Group type: EXPERIMENTAL
Intervention: LI 160 (600 mg/day)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: LI 160
Number of subjects: 151
Study: 10527975

Group type: EXPERIMENTAL
Intervention: Shared egg donation programme (donors)
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Shared egg donation programme (recipients)
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Donors >35 years
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Recipients >50 years
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Recipients >45 years
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection treatment for severe male factor infertility
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Endometriosis (in both groups)
Number of subjects: 1329
Study: 8577017

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN) at day 1, n = 4
Number of subjects: 9

Group type: COMPARATOR
Intervention: Delayed parenteral nutrition (PN) at day 5, n = 5
Number of subjects: 9
Study: 1832232

Group type: EXPERIMENTAL
Intervention: Laser thermal recanalization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional recanalization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional guide wire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hybrid laser probe
Number of subjects: 0
Study: 7050403

Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31950384

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (SEGT) combined with oncologic treatment (BRBC)
Number of subjects: 3327

Group type: COMPARATOR
Intervention: Oncologic treatment only (OT)
Number of subjects: 3327
Study: 30771790

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 600 mg/d for 3 months
Number of subjects: 50
Study: 28166118

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nonexercise Controls (CONT)
Number of subjects: 49
Study: 27125731

Group type: EXPERIMENTAL
Intervention: Patients expecting improvement/stabilisation (56%, N = 380)
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Patients expecting deterioration (8%, N = 55)
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Patients not knowing what to expect (21%, N = 144)
Number of subjects: 678
Study: 24140820

Group type: EXPERIMENTAL
Intervention: Relevant dimension primes in rule-based (RB) category learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irrelevant dimension primes in information-integration (II) category learning
Number of subjects: 0
Study: 21967242

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (hypoglycemic and antihypertensive agents)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents, and vitamin E)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents, and compound salvia tablets)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (83 healthy subjects)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 108
Study: 19408302

Group type: COMPARATOR
Intervention: No delay (<5 days)
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: Delay >or=5 days
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: Delay >or=7 days
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: Retesting of positive samples
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: Samples stored at room temperature
Number of subjects: 3767
Study: 17534979

Group type: EXPERIMENTAL
Intervention: rhDNase before ACT
Number of subjects: 24

Group type: COMPARATOR
Intervention: rhDNase after ACT
Number of subjects: 24
Study: 15469774

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene (pooled doses)
Number of subjects: 7705
Study: 11237229

Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin
Number of subjects: 56

Group type: COMPARATOR
Intervention: cephalothin plus netilmicin
Number of subjects: 56
Study: 9840853

Group type: EXPERIMENTAL
Intervention: 5 mL/kg of 0.35% lidocaine with 1:1,000,000 epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mL/kg of saline with 1:1,000,000 epinephrine
Number of subjects: 0
Study: 8018041

Group type: EXPERIMENTAL
Intervention: Patients with probable AD
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy age- and education-matched controls
Number of subjects: 10
Study: 2684698

Group type: EXPERIMENTAL
Intervention: PGE2 gel (2 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: PGE2 tablet (3 mg)
Number of subjects: 80
Study: 31808352

Group type: EXPERIMENTAL
Intervention: Sandal insole group (SI; n=34)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Plain sandal group (PS; n=32)
Number of subjects: 66
Study: 30807822

Group type: EXPERIMENTAL
Intervention: Lung dose ≥800 cGy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lung dose <800 cGy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lateral fields
Number of subjects: 127
Study: 25257861

Group type: EXPERIMENTAL
Intervention: Intravenous elemental iron (40 mg) administered at all three hemodialysis sessions in the first week (IW1 group: n=57)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intravenous elemental iron (40 mg) administered in the third week (IW3 group: n=53)
Number of subjects: 110
Study: 22717454

Group type: EXPERIMENTAL
Intervention: Etrolizumab (0.5 mg/kg SC, n=4)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Etrolizumab (1.5 mg/kg SC, n=5)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Etrolizumab (3.0 mg/kg SC, n=4)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Etrolizumab (4.0 mg/kg IV, n=5)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (n=5)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Etrolizumab (all doses in MD stage)
Number of subjects: 43
Study: 21375410

Group type: EXPERIMENTAL
Intervention: In-home wireless glucose monitor and transmitter (experimental group, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional arrangement (control group, n=50)
Number of subjects: 100
Study: 18178369

Group type: EXPERIMENTAL
Intervention: Topical morphine (1mL of morphine compounded at 10mg/mL in pluronic lecithin organogel applied to the wrist)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Subcutaneous morphine (1mL of 3mg/mL)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Topical drug-free PLO base (1mL)
Number of subjects: 5
Study: 16338812

Group type: EXPERIMENTAL
Intervention: Minimum Data Set‐Home Care (MDS‐HC)
Number of subjects: 925

Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 925
Study: 12556011

Group type: EXPERIMENTAL
Intervention: G-CSF and antibiotic therapy (n=8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Antibiotics alone (n=7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 15
Study: 10951246

Group type: EXPERIMENTAL
Intervention: Incident solar keratoses diagnosed during 12 months follow-up
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Regression of solar keratoses
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Recurrence of prevalent solar keratoses
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Net increase in solar keratosis numbers in men
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Net reduction in solar keratosis numbers in women
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Likelihood of developing additional solar keratoses
Number of subjects: 96
Study: 8849475

Group type: EXPERIMENTAL
Intervention: Postoperative spondylodiscitis (POD) group
Number of subjects: 875

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Treatment with antibiotics for POD
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) during acute phase
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: MRI during subacute phase
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: MRI three months after treatment
Number of subjects: 875
Study: 1501004

Group type: EXPERIMENTAL
Intervention: Prealbumin (PA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Albumin (Alb)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nutritional supplementation (energy balance and protein intake)
Number of subjects: 10
Study: 7006558

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of amitriptyline and IPT
Number of subjects: 0
Study: 31278280

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28395124

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Oxcarbazepine (OXC)
Number of subjects: 246
Study: 25497362

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for GAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 0
Study: 24037918

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest radiography (CXR)
Number of subjects: 0
Study: 20031380

Group type: EXPERIMENTAL
Intervention: Nut diet (30 g/day of raw nuts: 15 g walnuts, 7.5 g almonds, 7.5 g hazelnuts)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nut diet (30 g/day of raw nuts)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control diet (without nuts)
Number of subjects: 50
Study: 19572078

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate infusion (2 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 20
Study: 17295799

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with tablets of HDM extract (n = 55)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (n = 56)
Number of subjects: 111
Study: 15333701

Group type: EXPERIMENTAL
Intervention: Intravenous administration of (70)Zn or (67)Zn
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Plasma Zn concentration
Number of subjects: 5
Study: 12226038

Group type: EXPERIMENTAL
Intervention: High-output nebulizer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-output nebulizer
Number of subjects: 20
Study: 9575624

Group type: EXPERIMENTAL
Intervention: Contemnol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lithium carbonate
Number of subjects: 60
Study: 7867675

Group type: EXPERIMENTAL
Intervention: BAY x 7195 250 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BAY x 7195 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BAY x 7195 500 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2670019

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (ESTRADERM TTS‐50), 50 micrograms/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (medroxyprogesterone 10 mg/day for 12 days)
Number of subjects: 34
Study: 876804

Group type: EXPERIMENTAL
Intervention: Left ear presentation of pure tones
Number of subjects: 20

Group type: COMPARATOR
Intervention: Right ear presentation of pure tones
Number of subjects: 20
Study: 30826757

Group type: EXPERIMENTAL
Intervention: 2-day communication skills training (CST)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no CST before post-test)
Number of subjects: 172
Study: 28119433

Group type: EXPERIMENTAL
Intervention: AURAS‐AF software tool for automated risk assessment and reminders for OAC treatment.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (usual care).
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AURAS‐AF software tool for automated risk assessment.
Number of subjects: 47
Study: 26153191

Group type: EXPERIMENTAL
Intervention: EMDR therapy, performed in three sessions on alternate days for 45-90 minutes over four months.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comparison of mean depression level at post treatment between both groups.
Number of subjects: 60
Study: 24350936

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 654

Group type: COMPARATOR
Intervention: Control (other oral antidiabetic agents)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 654
Study: 21808751

Group type: EXPERIMENTAL
Intervention: Olanzapine ODT (10 to 20 mg, once daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Olanzapine SOT (10 to 20 mg, once daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Olanzapine ODT
Number of subjects: 23

Group type: COMPARATOR
Intervention: Olanzapine SOT
Number of subjects: 23
Study: 19558484

Group type: EXPERIMENTAL
Intervention: Educational intervention for nursing staff combined with consultation with a nurse specialist (RN level)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 241
Study: 17880439

Group type: COMPARATOR
Intervention: rFVIIa (NovoSeven)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VII25
Number of subjects: 0

Group type: COMPARATOR
Intervention: rFVIIa and VII25
Number of subjects: 0
Study: 15111514

Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Number of subjects: 231

Group type: COMPARATOR
Intervention: Human Soluble Insulin (HI)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Human Premix Insulin (MIX)
Number of subjects: 231
Study: 12421890

Group type: EXPERIMENTAL
Intervention: High-amount-high-intensity exercise (jogging 20 mi/week at 65-80% peak oxygen consumption)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Low-amount-high-intensity exercise (jogging 12 mi/week at 65-80% peak oxygen consumption)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Low-amount-moderate-intensity exercise (walking 12 mi/week at 40-55% peak oxygen consumption)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study: 9612831

Group type: EXPERIMENTAL
Intervention: Repeated counseling (RC)
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Previous antismoking advice by the GP
Number of subjects: 861
Study: 7794700

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study: 2801224

Group type: EXPERIMENTAL
Intervention: ATP test for bacteriuria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotics (trimethoprim) given as single dose or as a conventional 7-day regime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional urine culture
Number of subjects: 0
Study: 794090

Group type: EXPERIMENTAL
Intervention: 0.05% solution of N-monochloroglycine (GK-101) applied under pressure
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo solution of normal saline
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: GK-101 solution in conjunction with the pump system
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: GK-101 solution
Number of subjects: 61